Related Experiment Videos
[Cardiogenic shock caused by 5-fluorouracil].
C Mazet1, A Dellinger, D Vital Durand
1Service de Médecine interne, Centre Hospitalier Lyon-Sud, Pierre-Bénite.
Annales De Cardiologie Et D'Angeiologie
|March 1, 1990
Summary
The first dose of chemotherapy drug 5-fluorouracil (5-FU) caused severe heart shock in a patient. This highlights the need for careful monitoring during 5-FU treatment.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- 5-fluorouracil (5-FU) is a common chemotherapy agent.
- Cardiac toxicity of 5-FU, including anginal pain, is documented.
- Severe cardiac events like shock are less commonly reported.
Observation:
- A patient experienced severe, reversible cardiogenic shock after initial 5-FU chemotherapy.
- The shock was preceded by constrictive chest pain, without evidence of myocardial infarction.
- This represents a rare but significant adverse reaction to 5-FU.
Findings:
- Chemotherapy with 5-FU can induce acute, severe cardiogenic shock.
- Chest pain is a potential preceding symptom of 5-FU-induced cardiac toxicity.
- The cardiac toxicity is potentially reversible upon treatment cessation.
Implications:
- Clinicians should be vigilant for cardiac adverse events during 5-FU therapy.
- Daily clinical and electrocardiogram (ECG) monitoring may be warranted for patients on 5-FU.
- Early detection and intervention are crucial for managing 5-FU-induced cardiotoxicity.